184 related articles for article (PubMed ID: 34704597)
1. Expression and function of SLC38A5, an amino acid-coupled Na+/H+ exchanger, in triple-negative breast cancer and its relevance to macropinocytosis.
Ramachandran S; R Sennoune S; Sharma M; Thangaraju M; V Suresh V; Sneigowski T; D Bhutia Y; Pruitt K; Ganapathy V
Biochem J; 2021 Nov; 478(21):3957-3976. PubMed ID: 34704597
[TBL] [Abstract][Full Text] [Related]
2. Potent Inhibition of Macropinocytosis by Niclosamide in Cancer Cells: A Novel Mechanism for the Anticancer Efficacy for the Antihelminthic.
Sennoune SR; Nandagopal GD; Ramachandran S; Mathew M; Sivaprakasam S; Jaramillo-Martinez V; Bhutia YD; Ganapathy V
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765717
[TBL] [Abstract][Full Text] [Related]
3. Induction of Oxidative Stress and Ferroptosis in Triple-Negative Breast Cancer Cells by Niclosamide via Blockade of the Function and Expression of SLC38A5 and SLC7A11.
Mathew M; Sivaprakasam S; Dharmalingam-Nandagopal G; Sennoune SR; Nguyen NT; Jaramillo-Martinez V; Bhutia YD; Ganapathy V
Antioxidants (Basel); 2024 Feb; 13(3):. PubMed ID: 38539825
[TBL] [Abstract][Full Text] [Related]
4. SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer.
Shen X; Wang G; He H; Shang P; Yan B; Wang X; Shen W
Breast Cancer; 2024 Jan; 31(1):96-104. PubMed ID: 37914960
[TBL] [Abstract][Full Text] [Related]
5. Amino acid transporter SLC38A5 is a tumor promoter and a novel therapeutic target for pancreatic cancer.
Sniegowski T; Rajasekaran D; Sennoune SR; Sunitha S; Chen F; Fokar M; Kshirsagar S; Reddy PH; Korac K; Mahmud Syed M; Sharker T; Ganapathy V; Bhutia YD
Sci Rep; 2023 Oct; 13(1):16863. PubMed ID: 37803043
[TBL] [Abstract][Full Text] [Related]
6. Unconventional Functions of Amino Acid Transporters: Role in Macropinocytosis (SLC38A5/SLC38A3) and Diet-Induced Obesity/Metabolic Syndrome (SLC6A19/SLC6A14/SLC6A6).
Bhutia YD; Mathew M; Sivaprakasam S; Ramachandran S; Ganapathy V
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204736
[TBL] [Abstract][Full Text] [Related]
7. The
Taurino G; Chiu M; Bianchi MG; Griffini E; Bussolati O
Am J Physiol Cell Physiol; 2023 Aug; 325(2):C550-C562. PubMed ID: 37458433
[No Abstract] [Full Text] [Related]
8. Amino acid transporter SLC38A5 regulates developmental and pathological retinal angiogenesis.
Wang Z; Yemanyi F; Blomfield AK; Bora K; Huang S; Liu CH; Britton WR; Cho SS; Tomita Y; Fu Z; Ma JX; Li WH; Chen J
Elife; 2022 Dec; 11():. PubMed ID: 36454214
[TBL] [Abstract][Full Text] [Related]
9. SLC6A14 and SLC38A5 Drive the Glutaminolysis and Serine-Glycine-One-Carbon Pathways in Cancer.
Sniegowski T; Korac K; Bhutia YD; Ganapathy V
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33806675
[TBL] [Abstract][Full Text] [Related]
10. Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon Cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes.
Nguyen NT; Sennoune SR; Dharmalingam-Nandagopal G; Sivaprakasam S; Bhutia YD; Ganapathy V
Cells; 2024 May; 13(11):. PubMed ID: 38891084
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
12. Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.
Kim J; Okamoto H; Huang Z; Anguiano G; Chen S; Liu Q; Cavino K; Xin Y; Na E; Hamid R; Lee J; Zambrowicz B; Unger R; Murphy AJ; Xu Y; Yancopoulos GD; Li WH; Gromada J
Cell Metab; 2017 Jun; 25(6):1348-1361.e8. PubMed ID: 28591637
[TBL] [Abstract][Full Text] [Related]
13. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside CK induces apoptosis in triple-negative breast cancer cells by targeting glutamine metabolism.
Zhang B; Fu R; Duan Z; Shen S; Zhu C; Fan D
Biochem Pharmacol; 2022 Aug; 202():115101. PubMed ID: 35618001
[TBL] [Abstract][Full Text] [Related]
15. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.
Morotti M; Zois CE; El-Ansari R; Craze ML; Rakha EA; Fan SJ; Valli A; Haider S; Goberdhan DCI; Green AR; Harris AL
Br J Cancer; 2021 Jan; 124(2):494-505. PubMed ID: 33028955
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer.
Huang R; Wang H; Hong J; Wu J; Huang O; He J; Chen W; Li Y; Chen X; Shen K; Wang Z
Front Immunol; 2023; 14():1251643. PubMed ID: 37731509
[TBL] [Abstract][Full Text] [Related]
18. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
19. SLC38A5 aggravates DC-mediated psoriasiform skin inflammation via potentiating lysosomal acidification.
Zhu L; Xia X; Li G; Zhu C; Li Q; Wang B; Shi NX; Lei Z; Yang S; Zhang Z; Li H; Tan J; Liu Z; Wen Q; Zhong H; Lin XJ; Sun G; Bao X; Wang Q; Deng L; Bin L; Cao G; Yin Z
Cell Rep; 2023 Aug; 42(8):112910. PubMed ID: 37531255
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
